EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Stereotactic body radiotherapy of bone metastases in patients with head and neck squamous cell carcinoma – A multicenter cohort study

Alexander Rühle, Sebastian Schäfer, Isabell Prager, Mauro Loi, Pierluigi Bonomo, Viola Salvestrini, Marek Slavik, Petr Burkon, Fabian Lohaus, Kenneth Klischies, Olaf Wittenstein, Anna Sabrina Schunn und 15 weitere

Clinical and Translational Radiation Oncology · 2027-01 · 62 · 101336

DOI: 10.1016/j.ctro.2026.101336 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical and Translational Radiation Oncology, 2027-01. Verfasst von Alexander Rühle und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Medical Center Leipzig, Leipzig, Germany. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roland Ernst Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Bone metastases from head and neck squamous cell carcinoma (HNSCC) are a rare clinical entity, with limited data guiding management. This study aimed to evaluate the oncological outcomes of stereotactic body radiotherapy (SBRT) for this rare condition.

Methods

Patients who received SBRT for HNSCC-derived bone metastases between 2015 and 2024 were analyzed. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. The cumulative incidence of local failures (LF) and post-SBRT fractures was analyzed with death as competing event. Adverse events were graded according to CTCAE v5.0.

Results

Thirty-four patients with 54 irradiated bone metastases from 11 European centers were included. Median age was 63 years (range, 39-86); and the most common primary sites were the oropharynx (n = 12, 35.3%), nasopharynx (n = 8, 23.5%), and oral cavity (n = 5, 14.7%). The median prescribed biologically effective dose (BED10) was 60.0 Gy (IQR, 56.0-72.0 Gy). After a median follow-up of 23.3 months in patients alive at last contact, 2-year OS and PFS were 41.2% (95% CI, 24.3-57.3%) and 8.8% (95% CI, 2.3-21.1%), while the 2-year cumulative incidence of LF and fractures was 14.1% (95% CI, 3.0-27.8%) and 1.9% (95% CI, 0.0-6.9%). In exploratory analyses, patients treated for >1 bone metastases had inferior OS compared to those with a single treated bone metastasis (HR 2.58; 95% CI, 1.08-6.15; p = 0.033). Grade 3 adverse events occurred in one patient (2.9%), with no grade 4-5 events.

Conclusion

Although PFS remained limited, SBRT was associated with high local control and a low observed rate of severe adverse events in patients with HNSCC-derived bone metastases. Prospective studies are warranted to validate these findings and optimize patient selection.

Schlagwörter

Stichwörter der Autor:innen

Bone metastasesHNSCCHead and neck squamous cell carcinomaMDTMetastasis-directed therapySBRTStereotactic body radiation treatment

Autor:innen und Institutionen

  • Department of Radiation Oncology, University Medical Center Leipzig, Leipzig, Germany.
  • Comprehensive Cancer Center Central Germany, Partner Site Leipzig, Leipzig, Germany.
  • Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
  • Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Medical Faculty, Masaryk University, Brno, Czech Republic.
  • Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
  • National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-R…

Förderung

  • Roland Ernst Foundation

Zitieren

APA

Rühle, A., Schäfer, S., Prager, I., Loi, M., Bonomo, P., Salvestrini, V., Slavik, M., Burkon, P., Lohaus, F., Klischies, K., Wittenstein, O., Schunn, A. S., Drabke, S., Weissmann, T., Willner, J., von Wachter, C., Looman, E. L., Balermpas, P., Guckenberger, M., …, & Nägler, F. (2027). Stereotactic body radiotherapy of bone metastases in patients with head and neck squamous cell carcinoma – A multicenter cohort study. Clinical and Translational Radiation Oncology, 62, 101336. https://doi.org/10.1016/j.ctro.2026.101336

Vancouver

Rühle A, Schäfer S, Prager I, Loi M, Bonomo P, Salvestrini V, et al. Stereotactic body radiotherapy of bone metastases in patients with head and neck squamous cell carcinoma – A multicenter cohort study. Clinical and Translational Radiation Oncology. 2027;62:101336. doi:10.1016/j.ctro.2026.101336

BibTeX
@article{Rhle2027,
  author = {Rühle, Alexander and Schäfer, Sebastian and Prager, Isabell and Loi, Mauro and Bonomo, Pierluigi and Salvestrini, Viola and Slavik, Marek and Burkon, Petr and Lohaus, Fabian and Klischies, Kenneth and Wittenstein, Olaf and Schunn, Anna Sabrina and Drabke, Sophia and Weissmann, Thomas and Willner, Jochen and von Wachter, Camilla and Looman, Esmée L and Balermpas, Panagiotis and Guckenberger, Matthias and Ritter, Sebastian Michael and Moustakis, Christos and Mohamed, Ahmed Allam and Brunner, Thomas B and Blanck, Oliver and Boda-Heggemann, Judit and Nicolay, Nils H and Nägler, Franziska},
  title = {Stereotactic body radiotherapy of bone metastases in patients with head and neck squamous cell carcinoma – A multicenter cohort study},
  journal = {Clinical and Translational Radiation Oncology},
  year = {2027},
  volume = {62},
  pages = {101336},
  doi = {10.1016/j.ctro.2026.101336}
}
Kostenlos starten →